The Food and Drug Administration (Thai FDA) and the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) of the Republic of Poland are moving forward with the development of a Memorandum of Understanding (MOU) to promote cooperation on health product regulation, knowledge exchange, and capacity building between the two regulatory authorities. The cooperation aims to strengthen consumer protection, support access to quality, safe, and standard-compliant health products, and expand opportunities for Thai health products to enter the European Union market.

Thai FDA, led by Ms. Supattra Boonserm, Secretary-General of the Thai FDA, welcomed Dr. Grzegorz Cessak, President of URPL, and his delegation during their visit to Thailand. The two sides discussed potential areas of cooperation in health product regulation and jointly worked on a draft Memorandum of Understanding (MOU) between the two authorities.

Ms. Supattra Boonserm, stated that the discussion marked an important step toward establishing an MOU between the Thai FDA and URPL. The MOU will provide a framework for cooperation on health product regulation, knowledge exchange, and capacity building for both authorities. The two sides aim to sign the MOU in October 2026, marking the beginning of concrete cooperation and supporting the development of health products that meet internationally recognized standards of quality and safety.

Dr. Grzegorz Cessak expressed his pleasure in advancing the MOU between URPL and the Thai FDA, noting that it represents the first cooperation of its kind between the Thai FDA and a regulatory authority of a European Union Member State. He emphasized the importance of building networks among regulatory authorities to exchange knowledge, experience, and regulatory approaches. Such cooperation will enhance mutual understanding of the regulatory systems in both regions and further strengthen consumer protection. URPL also expressed interest in developing cooperation on the regulation of herbal products, an area in which Thailand has significant strengths.

Ms. Supattra Boonserm further stated that Thailand has strong potential in herbal products, particularly its distinctive and unique herbal raw materials, and is ready to develop cooperation with URPL in herbal product regulation, knowledge exchange, and collaborative activities related to clinical trials, an area in which URPL has expertise. The Thai FDA is committed to serving both as a regulator and a facilitator to foster innovation and create greater opportunities for Thai health products to compete and expand into the European Union market in the future.

...........................................................................................................
Publication date: 12 July 2026